吡非尼酮联合尼达尼布对特发性肺纤维化治疗的作用

Effect of Pirfenidone Combined with Nitanib in the Treatment of Idiopathic Pulmonary Fibrosis

目的:探讨吡非尼酮联合尼达尼布对特发性肺纤维化的治疗效果。方法:将2019年1月至2022年5月安阳市人民医院收治的100例特发性肺纤维化患者随机分为两组,每组50例。对照组患者在治疗时应用吡非尼酮,观察组患者在治疗时应用吡非尼酮联合尼达尼布,比较两组患者的治疗总有效率、不良反应发生率、血清炎症因子指标、血管内皮功能指标、肺通气功能指标、肺纤维化评分、生活质量评分。结果:与对照组相比,观察组患者的治疗总有效率更高,差异具有统计学意义(P <0.05)。在治疗后,与对照组比较,观察组患者中各项血清炎症因子指标、血管内皮素–1、肺纤维化评分均更低,观察组患者中内皮源性一氧化氮、第1秒用力呼气量(FEV1)、FEV1/肺活量(FVC)、生活质量评分均更高,差异均具有统计学意义(P <0.05)。两组患者不良反应发生率比较,差异无统计学意义(P> 0.05)。结论:吡非尼酮与尼达尼布联合治疗特发性肺纤维化的疗效良好,可减轻患者炎症反应、肺纤维化程度及血管内皮损伤,并改善患者肺通气功能,提升生活质量,且用药安全性良好。

Objective To investigate the therapeutic effect of pirfenidone combined with Nidanib on idiopathic pulmonary fibrosis. Methods A total of 100 patients with idiopathic pulmonary fibrosis admitted to Anyang People’s Hospital from January 2019 to May 2022 were randomly divided into two groups with 50 cases in each group. The control group was treated with pirfenidone, and the observation group was treated with pirfenidone combined with nidanib. The total effective rate, incidence of adverse reactions, serum inflammatory factor index, vascular endothelial function index, pulmonary ventilation function index,pulmonary fibrosis score and quality of life score of the two groups were compared. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant(P < 0.05). After treatment,the scores of serum inflammatory factors, vascular endothelin-1 and pulmonary fibrosis in the observation group were lower than those of the control group, and the scores of endodermal nitric oxide, forced expiratory volume in the first second(FEV1), FEV1/vital capacity(FVC) and quality of life were higher in the observation group, the differences were statistically significant(P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P > 0.05). Conclusion Pirfenidone combined with nidanib has good efficacy in the treatment of idiopathic pulmonary fibrosis, which can reduce inflammatory response,pulmonary fibrosis degree and vascular endothelial injury in patients, improve lung ventilation function and improve quality of life in patients, and the drug safety is good.